LJN 452

Drug Profile

LJN 452

Alternative Names: LJN452

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Non-alcoholic steatohepatitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary bile acid malabsorption; Primary biliary cirrhosis

Most Recent Events

  • 22 Dec 2016 LJN 452 receives Fast Track designation for Non-alcoholic steatohepatitis [PO,Capsule] in USA before December 2016
  • 01 Aug 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT02855164)
  • 17 Jun 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in Belgium (PO) after June 2016 (EudraCT2015-005215-33)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top